Stay updated on Merck & Co. Press Releases

Sign up to get notified when there's something new on the Merck & Co. Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Merck & Co. Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    Merck has announced the completion of its acquisition of the investigational B-cell depletion therapy CN201 and will present new long-term data for Tulisokibart in inflammatory bowel disease at UEG Week 2024, while several previous key studies involving KEYTRUDA have been removed from the site.
    Difference
    74%
    Check dated 2024-10-03T04:57:56.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Merck has announced significant updates including new approvals for KEYTRUDA® in Japan and positive EU CHMP opinions for its use in gynecologic cancers, while recent conference participation and trial results have been removed from the site.
    Difference
    77%
    Check dated 2024-09-25T22:38:02.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Recent updates highlight significant FDA approvals for Merck's KEYTRUDA® in various cancer treatments, including a combination therapy for malignant pleural mesothelioma and a notable survival benefit in triple-negative breast cancer, while several previous announcements regarding clinical trials and approvals have been removed.
    Difference
    80%
    Check dated 2024-09-18T16:47:10.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Recent updates include promising results for Ifinatamab Deruxtecan in small cell lung cancer and Merck's upcoming presentations at ESMO Congress 2024, while previous announcements about Daiichi Sankyo's agreement and Merck's financial results have been removed.
    Difference
    71%
    Check dated 2024-09-11T07:55:43.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The European Commission has approved Merck’s KEYTRUDA® in combination with Padcev® as a first-line treatment for advanced urothelial carcinoma, while Merck is also set to participate in an upcoming healthcare conference.
    Difference
    68%
    Check dated 2024-09-04T05:10:14.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Merck has initiated a Phase 3 trial for Bomedemstat aimed at treating essential thrombocythemia and received European Commission approval for WINREVAIR™ for pulmonary arterial hypertension, while recent updates include the removal of news about their acquisition of EyeBio and participation in AIDS 2024.
    Difference
    62%
    Check dated 2024-08-28T02:44:47.000Z thumbnail image

Stay in the know with updates to Merck & Co. Press Releases

Enter your email address, and we'll notify you when there's something new on the Merck & Co. Press Releases page.